Bolt Biotherapeutics Inc. (BOLT) |
|
3.63 -0.13 (-3.46%)
|
01-21 18:26 |
|
Open: |
3.69 |
Pre. Close: |
3.76 |
|
High:
|
3.8126 |
Low:
|
3.48 |
|
Volume:
|
169,133 |
Market Cap:
|
135M |
|
|
|
|
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.815 - 3.838 |
3.838 - 3.855 |
|
Low:
|
3.427 - 3.455 |
3.455 - 3.475 |
|
Close:
|
3.592 - 3.634 |
3.634 - 3.664 |
|
Technical analysis |
as of: 2022-01-21 4:25:13 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 5.25 One year: 6.03 |
| Support: |
Support1: 3.43 Support2: 2.85 |
| Resistance: |
Resistance1: 4.50 Resistance2: 5.16 |
| Pivot: |
4.00  |
| Moving Average: |
MA(5): 3.79 MA(20): 4.16
MA(100): 9.93 MA(250): |
| MACD: |
MACD(12,26): -0.65  Signal(9): -0.78 |
| Stochastic oscillator: |
%K(14,3): 21.19 %D(3): 22.22 |
| RSI: |
RSI(14): 34.14 |
| 52-week: |
High: 43.07 Low: 3.43 Change(%): -88.7 |
| Average Vol(K): |
3-Month: 391 10-Days: 273 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.BOLT has closed above bottom band by 27.2%. Bollinger Bands are 60.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to Bolt Biotherapeutics Inc.'s normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 06 Jan 2022
Bolt Biotherapeutics Doses First Patient with BDC-1001 in - GlobeNewswire
Fri, 19 Nov 2021
Bolt Biotherapeutics Announces Changes to its Board of Directors - GlobeNewswire
Fri, 12 Nov 2021
Bolt Biotherapeutics Presents New Preclinical Data on Three - GlobeNewswire
Fri, 01 Oct 2021
Bolt Biotherapeutics to Present Updates on Three Pipeline Programs - GlobeNewswire
Thu, 30 Sep 2021
Our First Look At Bolt Biotherapeutics - Seeking Alpha
Wed, 08 Sep 2021
Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors - GlobeNewswire
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
37 |
| Shares Float (M) |
13 |
|
% Held by Insiders
|
6.67 |
|
% Held by Institutions
|
94.87 |
|
Shares Short (K)
|
4,200 |
|
Shares Short P. Month (K)
|
4,360 |
Stock Financials |
|
EPS
|
-4.199 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
7.380 |
|
Profit Margin
|
|
|
Operating Margin
|
-10988.70 |
|
Return on Assets (ttm)
|
-26.1 |
|
Return on Equity (ttm)
|
-64.7 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-1.076 |
|
Sales Per Share
|
0.020 |
|
EBITDA (p.s.)
|
-2.188 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-52 |
|
Levered Free Cash Flow (M)
|
-41 |
Stock Valuations |
|
PE Ratio
|
-0.86 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.49 |
|
Price to Sales
|
179.96 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
